PNPLA3 and cryohydrocytosis: The current study, which examined these variants in the setting of Pakistani CHC patients, suggests that PNPLA3 and TM6SF2 polymorphisms seem to have no effect on serum markers of hepatic injury nor they associate with development of hepatic scarring following CHC infection.